Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 35 of 109 for:    fibromyalgia | Open Studies | Interventional Studies

A Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - University of Michigan (PERRFECT-UM)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University of Michigan
Sponsor:
Collaborator:
Cerephex Corporation
Information provided by (Responsible Party):
Daniel Clauw, MD, University of Michigan
ClinicalTrials.gov Identifier:
NCT01914679
First received: July 23, 2013
Last updated: August 5, 2014
Last verified: August 2014
  Purpose

The purpose of this study is to evaluate the mechanisms of noninvasive cortical electrostimulation therapy known as "Reduced Impedance Noninvasive Cortical Electrostimulation" RINCE)in the management of fibromyalgia. Patients who meet the 1990 American College of Rheumatology criteria for fibromyalgia will receive up to 24 RINCE treatments delivered by a medical device called "NeuroPoint". Approximately 20 patients will receive a combination of active and inactive (sham) therapy treatments over a 16-week period followed by a 4 week post-treatment evaluation. Patients will also undergo three (3) functional brain imaging scans while participating in the study: the first prior to the commencement of treatment, another mid-treatment; and the third at the completion of the treatment period.

The study's primary outcome measure will be the change from baseline in self-reported 24-hour average pain intensity. The study's hypothesis is that there will be a change in pain intensity as well brain functioning. We do not expect there to be a statistically significant improvement in pain intensity due to the small sample but do expect to see statistically significant changes in cortical function as measured by EEG and fMRI


Condition Intervention
Fibromyalgia
Device: RINCE

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Phase 2 Clinical Trial Evaluating Use of the NeuroPoint Medical Device as a Treatment for Fibromyalgia.

Resource links provided by NLM:


Further study details as provided by University of Michigan:

Primary Outcome Measures:
  • Change in patient 24-hour recall average pain intensity [ Time Frame: Assessed at 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
    Although pain is our primary outcome this study is not powered to detect a change in pain or other clinical parameters, it is a mechanistic study powered to detects changes in EEG and fMRI measures of connectivity that occur with RINCE treatment


Other Outcome Measures:
  • Change in network connectivity as measured by EEG [ Time Frame: Baseline (week 1), week 6, week 18 and week 21 ] [ Designated as safety issue: No ]
    EEGs will be measured at the baseline, week 4, week 18 and week 21 visits.

  • Investigate changes in neurocognitive functioning using the MASQ and MCS assessments. [ Time Frame: Baseline and up to 21 weeks ] [ Designated as safety issue: No ]
    The MASQ and MCS questionnaires will be administered at Baseline (week 1), week 6, week 10, week 14, week 18 and week 21.

  • fMRI measures of network connectivity [ Time Frame: Baseline (week 1), week 6, and week 18 ] [ Designated as safety issue: No ]
    Subjects will undergo a neuroimaging scan at Baseline (week 1), week 6, and week 18. The scan will measure network connectivity during stimuli.


Estimated Enrollment: 32
Study Start Date: July 2013
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Sham - no intervention
4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy.
Device: RINCE
The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
Other Name: RINCE therapy delivered by NeuroPoint Device
Active Comparator: 12-week RINCE
12 weeks of RINCE therapy involving 24 total treatments
Device: RINCE
The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
Other Name: RINCE therapy delivered by NeuroPoint Device

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must provide written informed consent and privacy authorization prior to participation in the study. Patient must have the ability to read and/or follow written and oral instructions, abide by the study restrictions, and agree to return for the required assessments.
  • Patient is female, 18-65 years of age (inclusive) at the time of consent.
  • Patient must have a confirmed diagnosis of fibromyalgia meeting the ACR 1990 diagnostic criteria for fibromyalgia.
  • Patients must have a 24-hour recall pain intensity score at both the screening and baseline visits between 40 and 90 inclusive on a 100 mm VAS scale.
  • Female patient of childbearing potential must be willing to use an acceptable method of birth control for the duration of their study participation.
  • Patients must be willing to refrain from all excluded therapies for the duration of the study.
  • In the opinion of the Investigator, the patient is willing and able to comply with all protocol-specified requirements.
  • Participants undergoing fMRI and 1H-MRS must be predominantly right handed (i.e. the subject writes with their right hand).

Exclusion Criteria:

The patient will not be eligible for enrollment if there is any history of, or in the opinion of the investigator, any of the following criteria are met:

  • Patient has a current significant psychological or psychiatric disorder (e.g., severe, unstable or poorly controlled depression, severe anxiety or obsessive-compulsive disorder; history of suicide attempt within preceding 5 years or suicidal ideation within preceding 6 months; or any history of bipolar disorder, schizophrenia, schizoaffective or other psychotic disorder).
  • Patient has a total Hospital and Anxiety Depression score of 11-21 for either anxiety or depression, or, based on the investigator's judgment, the patient is at risk of suicidal ideation or behavior.
  • Patient is currently using prohibited medications or treatments (see Prohibited Concomitant Therapy section of protocol) including stimulants, anesthetic patches, CPAP and/or TENS therapy.
  • Patient has an active diagnosis and is being treated for chronic infection or chronic condition such as lupus, rheumatoid arthritis, Parkinson's disease, multiple sclerosis, hepatitis, polio, seizures, or cancer (other than basal or squamous cell skin cancer).
  • Patient has any other chronic pain condition other than fibromyalgia that, in the Investigator's opinion, would interfere with the assessment of fibromyalgia (e.g., rheumatoid arthritis, post herpetic neuralgia, pain associated with diabetic neuropathy, severe pain due to degenerative joint disease, etc.)
  • Patient has history of seizure disorder, dementia or epilepsy anytime during his or her life except pediatric febrile seizures.
  • Female patient who is pregnant, planning a pregnancy, or breastfeeding.
  • Patient has any other disease or medical condition that, in the opinion of the investigator, would interfere with the evaluation of study device efficacy or safety, or would compromise the patient's ability to participate in or complete the study.
  • Patient has a history of other cranial electrical stimulation device use, or electroconvulsive therapy.
  • Patient has any metal implant, such as stents, aneurysm clips, shunts, pacemakers, defibrillators, neurostimulators or other contraindications with fMRI and 1H-MRS. Long-bone implants are not excluded.
  • Any anticipated need for surgery that might confound results or interfere with patient's ability to comply with the protocol.
  • Myocardial infarction during preceding 12 months, uncontrolled hypertension, active cardiac disease (American Heart Association Functional Class 2, 3 or 4 or Objective Class C or D), clinically significant cardiac rhythm or conduction abnormality, or anticipation of bypass or other cardiac surgery within the next 12 months.
  • Current systemic infection (e.g., HIV, hepatitis).
  • Patients receiving systemic corticosteroids (> 5 mg prednisone or equivalent per day).
  • Pending or current litigation or disability claim (including Workman's Compensation). Patients currently receiving disability benefits will require medical monitor approval on a case-by-case basis.
  • Patient has history of alcohol and/or drug abuse.
  • Patient has participated in any investigational study within 30 days prior to Screening visit or is currently participating in another clinical trial.
  • Patient has received any prior experimental treatment or therapy that, in the opinion of the medical monitor, would compromise the patient's ability to participate in the study.
  • Patient is a staff member or relative of a staff member at either the investigative site or the Cerephex Corporation.
  • Body Mass Index (BMI) of greater than approximately 40 kg/m2.
  • Claustrophobia or any other factor sufficiently significant that it is likely to prevent successful completion of fMRI and 1H-MRS procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01914679

Contacts
Contact: Megan Halvorson 1-734-998-6839 cpfrc-info@umich.edu
Contact: Kathy Scott cpfrc-info@umich.edu

Locations
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Megan Halvorson       cpfrc-info@umich.edu   
Sponsors and Collaborators
University of Michigan
Cerephex Corporation
Investigators
Principal Investigator: Daniel J Clauw, MD University of Michigan
  More Information

No publications provided

Responsible Party: Daniel Clauw, MD, Professor of Anesthesiology, University of Michigan
ClinicalTrials.gov Identifier: NCT01914679     History of Changes
Other Study ID Numbers: NPT-201-UM
Study First Received: July 23, 2013
Last Updated: August 5, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Michigan:
Fibromyalgia
Pain
Brain
Stimulation
Device
Treatment

Additional relevant MeSH terms:
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on November 25, 2014